Peregrine Pharmaceuticals reported $77.29M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agenus AGEN:US USD 208.35M 20.03M
Amgen AMGN:US USD 9.5B 4.3B
AstraZeneca AZN:LN USD 4.46B 359M
Biocryst Pharmaceuticals BCRX:US USD 461.19M 43.71M
Bristol Myers Squibb BMY:US USD 7.73B 3.02B
Celldex Therapeutics CLDX:US USD 18.58M 9.82M
Eli Lilly And LLY:US USD 2.62B 5.5M
GlaxoSmithKline GSK:LN GBP 3.61B 2.86B
Immunogen IMGN:US USD 309.51M 64.36M
Intrexon XON:US USD 9.07M 34.78M
Karyopharm Therapeutics KPTI:US USD 71.35M 10.9M
Macrogenics MGNX:US USD 83.99M 62.52M
Mannkind MNKD:US USD 54.31M 18.8M
Minerva Neurosciences NERV:US USD 40.22M 9.53M
Newlink Genetics NLNK:US USD 73.67M 5.84M
Novartis NOVN:VX USD 8.73B 5.1B
Novavax NVAX:US USD 1.28B 95.01M
Peregrine Pharmaceuticals PPHM:US USD 77.29M 37.84M
Repligen RGEN:US USD 573.36M 23.15M
Roche Holding ROG:VX 4.32B 2.54B
Xencor XNCR:US USD 52.65M 3.24M